How is Proteus syndrome diagnosed?

Proteus syndrome is a rare, complex, and progressive overgrowth disorder diagnosed primarily through strict clinical evaluation based on the Biesecker diagnostic criteria. Because the condition is caused by a mosaic post-zygotic mutation in the AKT1 gene, diagnosis relies on identifying a specific pattern of physical manifestations rather than a simple blood test, often leading to a challenging "diagnostic odyssey" for patients and families.

How is Proteus syndrome diagnosed clinically?

There is no single biomarker or routine blood test for Proteus syndrome. Diagnosis is based on the official clinical diagnostic criteria established by Biesecker et al. These criteria require the presence of specific findings, including the characteristic mosaic distribution of lesions, progressive overgrowth, and specific types of tumors or vascular malformations. Because Proteus syndrome presents with such high variability—meaning no two patients look exactly alike—physicians must look for a "constellation" of symptoms rather than a single indicator. Many patients face years of uncertainty, moving between specialists who may never have encountered the condition before, which is why clinical recognition by an expert is vital.

What role does genetic testing play in Proteus syndrome?

While the clinical criteria remain the gold standard, genetic testing has become an increasingly important tool for confirming Proteus syndrome. The condition is caused by a somatic activating mutation in the AKT1 gene. Because this mutation is mosaic—meaning it is present in only some cells of the body—it cannot be detected through a standard blood draw. Instead, clinicians must often perform a biopsy of the affected overgrowth tissue to find the mutation. If the AKT1 mutation is identified in the affected tissue but not in the blood, it provides definitive molecular confirmation of the diagnosis.

What are the key diagnostic criteria and differential diagnoses?

To ensure an accurate diagnosis, clinicians must distinguish Proteus syndrome from other overgrowth disorders. The diagnostic process involves ruling out conditions that share similar features, such as Klippel-Trénaunay syndrome, Cowden syndrome, or CLOVES syndrome. Key features that differentiate Proteus syndrome include:

• Cerebriform connective tissue nevi (CCTN): A pathognomonic, brain-like growth often found on the soles of the feet.


• Disproportionate overgrowth: Asymmetric and progressive growth of limbs, digits, or skull.


• Vascular malformations: Specifically capillary, venous, or lymphatic malformations.


• Specific tumor predisposition: Such as ovarian cystadenomas or parotid monomorphic adenomas.

Which specialists should be involved in the diagnostic journey?

Given the multisystem nature of Proteus syndrome, a multidisciplinary team is essential. Patients should ideally be evaluated by a clinical geneticist who has experience with overgrowth syndromes. Other specialists often involved include dermatologists, orthopedic surgeons, neurologists, and interventional radiologists. We understand that the "diagnostic odyssey"—the long, frustrating path of seeking answers—can be emotionally exhausting. If your current medical team is unfamiliar with Proteus syndrome, it is critical to seek a second opinion at a major academic medical center or a center of excellence that specializes in rare genetic overgrowth disorders.

Next steps

• Consult a Clinical Geneticist: Request a referral to a specialist familiar with AKT1-related disorders.


• Gather Records: Compile a timeline of all physical growth changes and previous imaging studies to assist the specialist.


• Connect with Peers: Join the Proteus syndrome community on DiseaseMaps.org to share experiences with the 5 other members who understand the unique challenges of this diagnosis.


• Request Specialized Imaging: Ensure that any necessary imaging (MRI or CT) is interpreted by radiologists with experience in rare vascular and overgrowth anomalies.

Medical disclaimer: This information is for educational purposes and should not replace professional medical advice, diagnosis, or treatment; always consult with your physician regarding your specific medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Proteus Syndrome.


• Orphanet: Proteus syndrome (ORPHA:744).


• OMIM (Online Mendelian Inheritance in Man): Proteus Syndrome (#176920).


• Biesecker, L. G., et al. (2011). "AKT1-activating mutation in Proteus syndrome." New England Journal of Medicine.